EW count suggests that Novo might be reversingMy count is disproportionate and wave 3 in (3) is not the smallest only on log scale. However, there are chances that the stock has reversed its trend.
Zigzag correction off the top might be done and I outlined a couple of leading diagonal scenarios that might play out.
What I really like is wave
Compare with Novo Nordisk A/S
Key facts today
Novo Nordisk (NOVO_B) defends suit vs Eli Lilly, saying Lilly used outdated Wegovy dosing in ads and ignored post‑approval data on the FDA‑cleared 7.2 mg regimen’s efficacy. 1
4.10 USD
15.49 B USD
46.74 B USD
3.35 B
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Details
Sector
Industry
CEO
Maziar Mike Doustdar
Website
Headquarters
Bagsværd
Founded
1923
IPO date
May 17, 1974
ISIN
US6701002056
CUSIP
670100205
FIGI
BBG000BQBKR3
Identifiers
ISIN US6701002056
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
$NVO , IdeaWeekly chart. A pharma giant at a crossroads.
NVO lost over 70% from its 2024 peak. The GLP-1 narrative cracked, competition arrived, and the market repriced brutally. Now at $43, it sits just above two major demand zones.
Two scenarios on the table:
Scenario 1 (yellow) : Capitulation into the $
NVO: Bullish Pennant Breakout Unlocks $+70$ Macro Target### **The Macro Picture**
Following a strong rally into early **2026**, **Novo Nordisk A/S ( NYSE:NVO $)** entered a healthy, multi-month consolidation phase. During this time, the price formed a textbook **Bullish Pennant** pattern, systematically carving out a series of lower highs and higher lows
Novo Nordisk (NVO) | 1D Technical AnalysisNovo Nordisk is approaching a critical technical inflection point after spending months in a primary downtrend. The recent price action is forming a Falling Wedge directly beneath the long-term descending trendline—a pattern that often precedes a bullish reversal when confirmed by a breakout.
Marke
Novo Nordisk (NOV)Novo Nordisk (NVO) reported strong first-quarter earnings on May 6, 2026, with sales jumping 32% to reach 96.8 billion Danish kroner (~$15.2 billion).
Driven by soaring demand for its popular GLP-1 weight-loss and diabetes drugs like Wegovy and Ozempic, the company beat earnings estimates and rais
NVO: Bullish Pennant Signals Potential Return to $150Novo Nordisk appears to be developing a compelling long-term reversal setup after a prolonged decline from its previous highs.
Following a significant selloff, price has spent several months building a base between $38 and $50. The recent recovery has pushed NVO back above a key psychological level
NVO: Weekly Falling Wedge Lines Up With Key FVGNovo Nordisk (NVO) is basing after an extreme drawdown — the stock ran from ~$40 to ~$150 through 2024, then gave nearly all of it back in a sharp decline back to the low $40s on GLP-1 competition and trial-data pressure.
Price just printed an +11.30% weekly reversal candle, closing at 48.07, and t
Downtrend Breakout Reversal.Novo Nordisk (NVO) currently represents a high-quality large-cap growth franchise in a transitional market phase, where fundamentals and technicals are beginning to realign after a significant sentiment-driven drawdown. The company remains structurally advantaged with dominant positioning in the GLP
$NVO (Novo Nordisk): 1-day. CUP & HANDLE breakout!NYSE:NVO (Novo Nordisk): 1-day
Six days later, and in my opinion it's still the best-looking chart among the large-cap names.
The price has reclaimed the green 200 MA ($47.8), which should now act as the main support zone if a pullback develops. I still think we're in Elliott Wave 3, so I'd consi
We're now on the verge of breaking above the channel.NYSE:NVO is now back above $50.
Bought the exact bottom and still fully long.
We're now on the verge of breaking above the channel. I think the higher-probability scenario is that we've transitioned into a trading range (yellow).
If that's the case, we're now around the middle of that range, mak
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Maturity dateNov 20, 2045
Coupon4.00% (Fixed)
Maturity dateFeb 20, 2038
Coupon3.63% (Fixed)
Maturity dateMay 27, 2037
Coupon3.63% (Fixed)
Maturity dateFeb 20, 2035
Coupon3.38% (Fixed)
Maturity dateMay 21, 2034
Coupon3.38% (Fixed)
Maturity dateMay 27, 2033
Coupon3.13% (Fixed)
Maturity dateFeb 20, 2032
Coupon3.00% (Fixed)
Maturity dateJan 21, 2031
Coupon3.25% (Fixed)
Maturity dateAug 27, 2030
Coupon2.88% (Fixed)
Maturity dateFeb 20, 2029
Coupon2.50% (Fixed)
Maturity dateJan 21, 2029
Coupon3.13% (Fixed)
See all NVO bonds









